FDA green­lights la­bel up­date to Gilead­'s Bik­tarvy to in­clude more da­ta in preg­nant peo­ple

The FDA on Fri­day ap­proved a la­bel up­date on Bik­tarvy, Gilead’s block­buster HIV drug, to in­clude more da­ta on the drug’s safe­ty and ef­fi­ca­cy for preg­nant peo­ple with HIV.

The ad­di­tion­al da­ta re­flect­ed on the la­bel are sup­port­ed by pos­i­tive re­sults from Gilead’s Study 5310, which eval­u­at­ed Bik­tarvy in preg­nant peo­ple with HIV-1 who have sup­pressed vi­ral loads, mean­ing that they have a low lev­el of virus in their bod­ies. The study eval­u­at­ed peo­ple in their sec­ond and third trimesters through a me­di­an of 16 weeks post­par­tum.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER